Toxoflasma gondii tachyzoites markedly alter the profile of eicosanoids released by human mononuclear phagocytes. Freshly isolated, 2-h adherent human monocytes release both cyclooxygenase (e.g., thromboxane [TX] B2, prostaglandin [PG] E2) and 5-1ipoxygenase (e.g., leukotriene [LT] ]]4, LTC4) products of arachidonic acid metabolism after stimulation by the calcium ionophore A23187 or ingestion of opsonized zymosan particles or heat-killed T. gondii. However, after incubation with viable T. gondii, normal and chronic granulomatous disease monocytes release only the cyclooxygenase products TXB2 and PGE2 and fail to form LTB4, LTC4, or other 5-1ipoxy-genase products. Monocytes maintained in culture for 5 d lose this capacity to release TXB2 and PGE2 after incubation with T. gondii. T. gondii significantly inhibit calcium ionophore A23187-induced LTB4 release by monocyte-derived macrophages; heat-killed organisms do not affect this calcium ionophore A23187-induced release of LTB4. T. gondii-induced inhibition of LTB4 release by calcium ionophore A23187-stimulated monocyte-derived macrophages is reversed by interferon (IFN)-3' treatment of the monolayers. LTB4 induced extensive damage to the cellular membranes and cytoplasmic contents of the organisms as observed by transmission electron microscopy. Exogenous LTB4 (10-6 M) induced intracellular killing of ingested T. gondii by non-IFN-q,-treated monocyte-derived macrophages. IFN-y-induced antitoxoplasma activity in monocyte-derived macrophages was inhibited by the selective 5-1ipoxygenase inhibitor zileuton but not by the cyclooxygenase inhibitor indomethacin. These findings suggest a novel role for 5-1ipoxygenase arachidonic acid products in human macrophage IFN-3,-induced antitoxoplasma activity.
H
uman monocytes, but not monocyte-derived macrophages, are cytotoxic to Toxoplasma gondii, an obligate intracellular protozoal parasite (1) (2) (3) . Monocytes possess a granule peroxidase identical to myeloperoxidase (MPO) 1 of neutrophils and respond to stimulation with a respiratory burst leading to the formation of superoxide anion (Of) and hydrogen peroxide (H202) (4) . Monocytes derived from peripheral blood and maintained as adherent cells in culture undergo a variety of biochemical and morphologic changes and differentiate into cells resembling tissue macrophages (5) (6) (7) . During this transformation in culture, there is a progressive loss of the granule peroxidase (5, 8) ; after an initial rise at day 3, H202 release also greatly decreases (9) . Treatment of lular pathogens as T. gondii (1) (2) (3) and L. donovani (14, 17) .
Chronic granulomatous disease (CGD) monocytes that fail to undergo a respiratory burst have a marked impairment in toxoplasmacidal and toxoplasmastatic activities (2) . However, their toxoplasmastatic activity is augmented by IFN-3' treatment, suggesting activation of an oxygen-independent antiprotozoal system in these phagocytes (2) .
As observed in human monocyte-derived macrophages, T.
gondii inhibit respiratory burst activity and phagolysosomal fusion in resident murine peritoneal macrophages (18, 19) .
Furthermore, T. gondii alter the metabolism of arachidonic acid in murine peritoneal macrophages. Resident routine macrophages release the 5-1ipoxygenase arachidonate products leukotriene (LT) B4 and LTC4 after incubation with the calcium ionophore A23187 and LTC4 and LTD4 after ingestion of opsonized zymosan particles (19) . In contrast, T. gondii inhibit 5-1ipoxygenase product release and shift arachidonic acid metabolism to monohydroxyeicosatetraenoic acid (HETE) (i.e., 11-, 12-, and 15-HETE) release by these macrophages. Viable
T. gondii are required for this alteration in arachidonic acid metabolism since heat-killed T. gondii induce release of LTDa but not mono-HETEs from the murine macrophages (19) . We report here that human mononuclear phagocyte eicosanoid metabolism is altered by T. gondii tachyzoites.
Whereas 5-1ipoxygenase arachidonate products (LTB4, LTC4) are released by freshly isolated human peripheral blood monocytes incubated with soluble (i.e., the calcium ionophore A23187) or particulate (i.e., opsonized zymosan or heat-killed T. gondii) stimuli, viable T. gondii fail to induce 5-1ipoxygenase product release by these cells. Furthermore, T. gondii inhibit LTBa release by calcium ionophore A23187-stimulated monocyte-derived macrophages; this inhibitory effect is reversed by IFN-% We also report that LTBa exerts potent cytotoxic activity against T. gondii. The selective 5-1ipoxygenase
inhibitor zileuton but not the cyclooxygenase inhibitor indomethacin blocks IFN-y-induced antitoxoplasma activity in monocyte-derived macrophages. These data suggest that inhibition of macrophage LT release may be an important mechanism used by T. gondii in their evasion of host inflammatory responses.
Materials and Methods
Special Reagents. LTB4, LTC4, LTD4, 5-HETE, 11-HETE, 12-HETE, 15-HETE, PGE2, 6-keto-PGFa~, and thromboxane (TX) B2 were obtained from Cayman Chemical Co., Inc. (Ann Arbor, MI). These eicosanoids were supplied in ethanol with dilutions made in PBS. 3H-LTB4, 3H-LTC4, 3H-PGE2, 3H-6-keto-PGFl~, and 3H-TXB2 were obtained from New England Nuclear (Boston, (7), venous blood was collected in 0.5% K2 EDTA, diluted 1:1 (vol/vol) with Ca 2 § PBS, centrifuged at 125 g for 20 min at 4~ and the platelet-containing supernatants discarded. After washing in Ca2 § PBS, the cell pellets were resuspended in Ca2+/Mg2+-free PBS containing 0.3 mM Na2EDTA and underlayered with Histopaque 1077 (Sigma Chemical Co., St. Louis, MO) at a ratio of 1.5:1 (cell suspension/Histopaque; vol/vol) before centrifugation at 800 g for 25 min at 23~ (22) . The mononuclear cells located in the Ca 2 § PBS:Histopaque interface were collected, washed twice with Ca2+/Mg2+-free PBS, and resuspended in RPMI 1640 media buffered with 10 mM Hepes (Whittaker M.A. Bioproducts, Walkersville, MD) and supplemented with 2 mM r-glutamine, 25 U/ml penicillin G, and 25 #g/ml streptomycin (GIBCO BILL, Gaithersburg, MD). At a concentration of 3 x 106 monocytes per milliliter, the cells were added to sterile 60 x 15 mm tissue culture plates (Falcon 3801 Primaria; Becton Dickinson & Co., Mountain View, CA) and allowed to adhere for 2 h at 37~ in 5% CO2/95% air with humidity. The plates were washed with sterile PBS to remove nonadherent cells. Adherent monocytes were either used immediately or maintained for 5 d in culture to obtain monocyte-derived macrophages, with RPMI media containing 10-15% autologous serum changed daily. Some monolayers were stained with Diffquik (Difco Laboratories, Inc., Detroit, MI) for evaluation of cell morphology or benzidine dihydrochloride to detect peroxidase (23) . In some studies, the media contained 100 U/ml recombinant human IFN-y. All buffers and media were prepared with sterile nonwrogenic water (Baxter Healthcare Corp., Deerfield, IL) and were filtered before use with 0.22 #m filter units (Corning Inc., Corning, NY). All glassware had been heated for 24 h at 170~ to destroy endotoxin.
T. gondii. The T. gondii RH strain was maintained by intraperitoneal passage in BALB/c mice (21) . After lavage with Ca2+/Mg~+-free PBS, the peritoneal fluid was filtered through a 3-#m polycarbonate filter (Nucleopore Corp., Pleasanton, CA) to remove leukocytes. The T. gondii were centrifuged at 1,000 g for 15 min at 4~ washed twice with Ca2+/Mg2 § PBS, and resuspended in PBS before use. The organisms were >95% viable as assessed by trypan blue exclusion (24) . In selected studies, T.
gondii were killed by heating at 100~ for 5 rain.
Eicosanoid Studies. The zymosan particles were washed free of unbound serum components before addition to the monolayers. At the completion of the incubation periods, the reaction mixtures were collected, centrifuged at 250 g for 10 min at 4~ and the supernatants stored at -70~ until assayed for eicosanoids by HPLC or RIA. The reaction mixture supernatants underwent solid phase extraction with I ml octadecyl Baker-10 columns (J. T. Baker Chemical Co., Phillipsburg, NJ) (25) . The eluants were evaporated to dryness under nitrogen, resuspended in methanol, and centrifuged at 3000g for 5 rain at 4~ The clear supematant underwent reversephase HPLC on a 5#zm particle size 2.1 x200 mm Cls microbore column (Hypersil ODS; Hewlett-Packard Co., Palo Alto, CA) with use of methanol/water/acetic acid (75:25:0.01, vol/vol/vol), pH 4.7, at a flow rate of 1 ml/min. A liquid chromatograph with diode array detector (models 1090 and 1040; Hewlett-Packard Co.) were used to monitor eluting peaks at 235 and 270 nm with rapid UV spectral scanning for identification of compounds that cochromatographed with authentic LT and HETE standards (26 (27) . The LTB4 antiserum had a sensitivity of 10 pg per 0.1-ml sample and the following cross-reactivities 20-COOH-LTB4, 0%; 5-HETE, 0.2%; LTC4, 0.02%; LTD4, 0.04%; LTE4, 0.15%, LTF4, 0%; and arachidonic acid, 0%. The LTC4 antiserum had a sensitivity of 20 pg per 0.1-ml sample and the following cross-reactivities at B/Bo 50%: (5S, 6R)-LTC4, 100%; LTD4, 43%; 11-trans-LTD4, 47%; LTE4, 6%; LTF4, 50%; (5R, 6R)-LTC4, 100%; (5S, 6S)-LTC4, 1.7%; (SR, 5S)-LTC4, 0.7%; LTC4-sulfone, 10%; LTD4-sulfone, 7%; LTE4-sulfone, 0.4%; LTF4-sulfone, 1.0%; and LTB4, (5S, 6R)-7,8,9,10,11,12, 14,15-octahydro-LTC4, PGE2, PGF2~, glutathione, 5-HETE, and arachidonic acid, each <0.2%.
The PGE2, 6-keto-PGFl,, and TXB2 antisera were produced in rabbits in our laboratory (28, 29) by the method of Jaffe and Behrman (30) . The PGE2 antiserum at a dilution of 1:6,000 had a sensitivity of 10 pg per 0.1-ml sample and the following crossreactivities at B/Bo 50%: PGE2, 100%; PGD2, 0.8%; PGEa, 9.3%; 6-keto-PGE2, 2.0%; PGFI~, 0.3%; 6-keto-PGFl~, 2.2%; and PGFz~, 1.0%. The 6-keto-PGF~ antiserum at a dilution of 1:6,000 had a sensitivity of 10 pg per 0.1-ml sample and the following cross-reactivities at B/Bo 50%: 6-keto-PGFl~, 100%; PGD2, 0.42%; PGE1, 0.1%; PGE2, 0.11%, 6-keto-PGE2, 2.5%, PGF2,~, 1.43%; and PGF~, 0.77%. The TXB2 antiserum at a dilution of 1:100,000 had a sensitivity of I pg per 0.1-ml sample and the following cross-reactivities at B/Bo 50%: TXB2, 100%; PGD2, 0.53%; PGF2,,, <0.2%; and 6-keto-PGE2, PGF~, and 6-keto-PGF~, each <0.02%.
Morphologic Studies. T. gondii (2 • 107) were incubated for 30 rain at 37~ in PBS in the absence or presence of LTB4 at the concentrations indicated in the legends to Figs. 4 and 5. The preparations were then centrifuged at 1,000 g for 15 rain before fixation. In studies to assess antitoxoplasma activity of LTB4, human monocyte--derived macrophages incubated in the absence of IFN-3' for 5 d were challenged with T. gondii (1:5 ratio, macrophage:organism) for 30 rain at 37~ washed three to five times in CaZ § 2+-free PBS, and incubated in the absence or presence of 10 -6 M LTB4
in RPMI media containing 10% autologous serum for 60 min at 37~ The preparations were washed again in CaZ § PBS and incubated in RPMI media with 10% autologous serum for an additional 23 h at 37~ in 5% C02/95% air with humidity. The samples were fixed in 4% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, for 2 h. The samples were prepared for transmission electron microscopy, with thin sections placed on a 200-mesh grid coated with 1% Parlodion (Mallinckrodt Inc., St. Louis, MO) and examined on an electron microscope (model 100B; JEOL Ltd., Tokyo, Japan) at 60 kV as described previously (31) .
The distribution of morphologic changes induced in the T. gondii after incubation with LTB4 was determined by morphometric analysis as described previously (31, 32) . The organisms were classified as exhibiting either no cytotoxic changes or one of the following cytotoxic characteristics: (a) intracellular vacuole formation; (b) extrusion of cytoplasm into the space between the inner and outer surface membrane units; (c) extracellular release of cytoplasmic material; or (d) surface membrane vesiculation and disruption. 10 randomly selected fields in each grid were photographed at a magnification of 7,000 for morphometric analysis. The role of cyclooxygenase versus 5-1ipoxygenase arachidonic acid products in macrophage antitoxoplasma activity was also assessed. Monocyte-derived macrophages adherent to 22-mm square glass coverslips were incubated in RPMI media containing 10% autologous serum and IFN-3' (100 U/ml) for 5 d in 5% COJ95% air with humidity. After washing, the monolayers were incubated with freshly isolated T. gondii (1:5 ratio, macrophage:organism) in media alone or media containing either the cyclooxygenase inhibitor indomethacin (10 -6 M) (33) or the 5-1ipoxy-genase inhibitor zileuton (10 -6 M) (20, 34) for 30 rain at 37~ Noningested organisms were then removed by washing, and the cell monolayers were either fixed with 5% formalin (time 0) or incubated in RPMI media containing 10% autologous serum in the absence or presence of indomethacin or zileuton for an additional 6 h before fixation in 5% formalin. After staining with Giemsa, the number of intracellular T. gondii per macrophage was assessed by light microscopy at a magnification of 400 by use of a Whipple micrometer disc (Bausch & Lomb Inc., Rochester, NY). To confirm that zileuton is a selective inhibitor of the 5-lipoxygenase pathway under the conditions of these experiments, IFN-y-treated monocyte-derived macrophages after incubation with 10 -6 M zileuton for 30 min were stimulated with the calcium ionophore A23187 (10 #M) for 20 min at 37~ The supernatants of the reaction mixtures were assayed for the 5-1ipoxygenase product LTB4 and the cyclooxygenase product TXB2 by RIA as described above.
Statistical Analysis. The data are reported as the mean _+ SE of the combined experiments. Differences were analyzed for significance (p <0.05) by Student's two-tailed t test for independent means.
Results
Monocytes. Greater than 95% of freshly isolated (2-h adherent) normal human monocytes were peroxidase positive and had the characteristic morphology of monocytes by light microscopic evaluation of Diffquik-stained preparations. Human monocytes incubated in buffer alone for 90 rain released low levels (<33 pg per 105 monocytes) of each of the following eicosanoids: LTB4 and LTC4 (Figs. 1 A and 2) and TXB2, PGE2, and 6-keto-PGFl,~ (Fig. 2) ; 5-, 11-, 12-, and 15-HETE were not detected in these monocyte supernatants. 63% of the total eicosanoids released by these control monocytes were cyclooxygenase products (Fig. 3) . T. gondii incubated in buffer alone for 90 min release PGE2 (73.4 pg per 106 organisms in 90 min as we have previously reported [21] ) but do not generate mono-HETEs or 5-1ipoxygenase products.
When human monocytes were incubated with T. gondii or opsonized zymosan particles (1 mg/ml), or for 20 min with the calcium ionophore A23187 (2.5 #M). In some studies, the phagocytes were incubated at 37~ for 90 min with either viable or heat-killed T. gondii followed by incubation for an additional 20 min with the calcium ionophore A23187 (2.5 #M). Cyclooxygenase (i.e., PGE2, 6-keto-PGFl~,, and TXB2) and 5-1ipoxygenase (i.e., LTB4 and LTC4) arachidonate products were assayed by RIA as described in Materials and Methods. The number of studies performed for each condition is shown within the 6-keto-PGF1~ graph. *p <0.05 compared with control (i.e., monocytes, day-5 monocytederived macrophages, or IFN-7-treated day-5 monocyte-derived macrophages incubated in buffer alone). ~p <0.05 compared with non-IFN-"y-treated day-5 monocyte-derived macrophages. of total eicosanoids assayed, Fig. 3 ). T. gondii did not stimulate a significant release of LTB4, LTC4 (Figs. 1 B and 2) , or 6-keto-PGF~,~ (Fig. 2) , or 5-, 11-, 12-, or 15-HETE (not shown) above that by monocytes alone. Similarly, freshly isolated CGD monocytes failed to release LTB4 or LTC4 (Fig.  1 C) but did generate TXB2 (mean 399 pg per 10 s cells, n = 2) and PGE2 (mean 227 pg per 105 cells, n = 2) after incubation with T. gondii. 88.7 (Fig. 3) and 91.8% of eicosanoids released by T. gondii-stimulated normal and CGD monocytes, respectively were cyclooxygenase products.
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In contrast, heat-killed T. gondii significantly increased LTB4 (p <0.05), TXB2 (p <0.02), and PGE2 (p <0.05) release above control (Fig. 2) . Approximately equal amounts The percentage of each cyclooxygenase (CO) (i.e., PGE2, 6-keto-PGF1~, and TXB2) and 5-1ipoxygenase (5-LO) (i.e., LTB4 and LTC4) product of the total eicosanoids assayed for each experimental condition described in Fig. 2 is shown.
noid released (Figs. 1 D, 2, and 3) . Incubation of the monocytes with either viable or heat-killed T. gondii before calcium ionophore A23187 stimulation did not alter significantly the amount of LTB4 or other eicosanoids released compared with that released by monocytes incubated with calcium ionophore A23187 alone (Figs. 2 and 3 ).
Monocyte-derived Macrophages. Human peripheral blood monocytes were maintained in culture for 5 d, during which period they lose their endogenous peroxidase activity (7, 9) .
T. gondii failed to stimulate the release of TXB2, PGE2, 6-keto-PGFl~, LTB4, LTC4 (Fig. 2) , or mono-HETEs (not shown) by the day 5-adherent monocyte-derived macrophages compared with controls. Although the total amount of eicosanoids released by zymosan-and calcium ionophore A23187-stimulated monocyte-derived macrophages decreased by 2.7-and 12.7-fold, respectively, compared with freshly isolated monocytes, these cultured cells remained capable of eicosanoid release (Fig. 2) . Compared with unstimulated cultured cells, TXB2 release by the day 5-adherent cells was increased 4.1-fold (p <0.02) by incubation with zymosan. As with freshly isolated monocytes, cyclooxygenase products (80.2% of eicosanoids assayed) were the predominant arachidonate metabolites released by the zymosan-stimulated monocyte-derived macrophages (Fig. 3) . The calcium ionophore A23187 increased day 5 monocytederived macrophage release of TXB2 by 8.1-fold (p <0.05) and LTB4 by 30.6-fold (p <0.001) compared with controls (Fig. 2) . LTB4 (61.8% of assayed eicosanoids) was the predominant arachidonate product released by calcium ionophore A23187-stimulated monocyte-derived macrophages (Fig. 3) . Prior incubation of the monocyte-derived macrophages with viable T. gondii before calcium ionophore A23187 stimulation significantly inhibited the ionophore-induced release of 5-1ipoxygenase products by these cells. An 8.7-fold reduction (p <0.02) in the calcium ionophore A23187-stimulated of LTB4 (116 pg per 10 s cells) and TXB2 (126 pg per 105 cells) were released by monocytes incubated with heat-killed T. gondii (Fig. 2) . Opsonized zymosan induced LTB4 (p <0.001), LTC4 (p <0.05), and TXB2 (p = 0.0001) release above background levels (Fig. 2) . As in T. gondii-stimulated cells, cyclooxygenase products were the principal eicosanoids released by heat-killed T. gondii-and zymosan-stimulated monocytes (67 and 68%, respectively of total eicosanoids assayed, Fig. 3) .
The soluble stimulus calcium ionophore A23187 induced both a marked increase in the total amount and a change in profile of eicosanoids released by the human monocytes compared with that induced by T. gondii or zymosan particles.
Calcium ionophore A23187-induced eicosanoid release was 17.0-, 30.4-, and 16.1-fold greater than that stimulated by freshly isolated T. gondii, heat-killed T. gondii, and zymosan respectively (Fig. 2) . 5-Lipoxygenase products constituted 89.5% of the assayed arachidonate metabolites produced by calcium ionophore A23187-stimulated cells with LTB4 (79.2% of total eicosanoids assayed), the predominant eicosa- 1641 Yong et al. were randomly selected and examined for these studies.
release of LTBa by these cells was observed (Fig. 2) ; this level of LTB4 was not significantly different from that released by day 5 cells alone. In contrast, prior incubation of the monocytederived macrophages with heat-killed T. gondii did not affect the calcium ionophore A23187-induced release of eicosanoids by these monolayers (Figs. 2 and 3 ).
IFN-T-treated Monocyte-derived Macrophages. Monocytes
were maintained in culture for 5 d in the presence of IFN-y (100 U/ml). IFN-y treatment did not significantly alter the release of either cyclooxygenase or 5-1ipoxygenase products by monocyte-derived macrophages incubated with T. gondii (viable or heat killed), zymosan, or the calcium ionophore A23187 alone compared with similarly stimulated cells incubated in the absence of IFN-y (Fig. 2) . However, IFN-y restored the ability of T. gondii-infected monocyte-derived macrophages to release LTB4 after stimulation with the calcium ionophore A23187. Calcium ionophore A23187-stimulated release of LTB4 by T. gondii-infected monocyte-derived macrophages was augmented 14.5-fold (p <0.02) in IFNy-treated cells compared with cells incubated in the absence of IFN-y (Fig. 2) . LTB4 constituted 67.3% of eicosanoids released by the IFN-y-supplemented monolayers stimulated with calcium ionophore A23187 after prior incubation with T. gondii (Fig. 3) .
Since (a) T. gondii fail to stimulate either LTB4 or LTCa release by human mononuclear phagocytes, (b) IFN-y reverses

T. gondii-induced suppression of LTBa generation in mono-
cyte-derived macrophages, and (c) IFN-y stimulates macrophage toxoplasmacidal activity (1-3), we examined whether 5-1ipoxygenase arachidonic acid products exert cytotoxic activity against these organisms. As determined by morphometric analysis of transmission electron micrographs, LTBa (10-1~ M) induced cytotoxic changes in the T. gondii (Fig. 4) . 28.1% of the tachyzoites showed evidence of cytotoxic injury after incubation with 10 -6 M LTB4 in PBS for 30 min compared with 2% of control organisms incubated in buffer either alone (Fig. 4) or containing 0.5% ethanol (vehicle control, not shown). LTB4-induced antitoxoplasma activity was not significantly affected by the presence of serum;
24.9% of T. gondii tachyzoites (n = 169) exhibited cytotoxic changes after incubation for 30 min in PBS containing 10 -6 M LTB4 and 10% heat-inactivated normal serum that was negative for Toxoplasma-specific IgG and IgM antibodies.
LTB4-mediated cytotoxic changes included surface membrane vesiculation, extravasation of cytoplasmic contents into a space between the inner and outer surface membrane units, and cytoplasmic vacuolization in the T. gondii (Fig. 5 ).
LTB4 also promoted intracellular killing of ingested T.
gondii tachyzoites by day 5 monocyte-derived macrophages (Fig. 6) . Non-IFN-y-treated monocyte-derived macrophages after incubation with T. gondii for 30 min were then washed to remove noningested organisms and incubated in the absence or presence of LTB4 (10 -6 M) for 60 min at 37~ After washing, the monolayers were maintained in media containing 10% autologous serum and examined by transmission electron microscopy at 24 h. Whereas replication of normal-appearing T. gondii in monocyte-derived macrophages was observed 24 h after ingestion of organisms (Fig. 6 A) ,
T. gondii replication was inhibited by incubation of the cells after ingestion of organisms with 10 -6 M LTB4 (Fig. 6 B) . The phagocytic vacuoles in the LTB4-treated cells contained damaged T. gondii of irregular shape and altered internal organelle structure. Close association of macrophage mitochondria with the surface of parasite vacuoles observed in T.
gondii-infected cells (Fig. 6 A) was not present in cells after LTBa treatment (Fig. 6 B) . The role of cyclooxygenase versus 5-1ipoxygenase products in IFN-y-induced macrophage antitoxoplasma activity was next examined. IFN-y-treated day-5 monocyte-derived macrophages were incubated with T. gondii in the absence or presence of either the cyclooxygenase inhibitor indomethacin (33) or the 5-1ipoxygenase inhibitor zileuton (20, 34) for 30 min at 37~ After washing, the incubations were either terminated by formalin fixation of the monolayers (0 h) or continued in media alone or media containing indomethacin or zileuton for an additional 6 h before fixation. IFN-y-treated day-5 monocyte-derived macrophages exerted antitoxoplasma activity (Fig. 7) . There was no significant increase in the number of T. gondii present in the IFN-y-treated macrophages at 6 h (1.6 _+ 0.3 T. gondii per macrophage) compared with 0 h (1.1 + 0.2 T. gondii per macrophage, p --0.3028) (Fig.   7 ). IFN-y-induced macrophage antitoxoplasma activity was not significantly affected by cyclooxygenase inhibition by indomethacin (10 -6 M). In contrast, the number of T. gondii per macrophage was increased 6.6-fold (6.6 _+ 0.8 T. gondii per macrophage, p = 0.0028) at 6 h compared with 0 h (1.0 +_ 1 T. gonclii per macrophage) in the monolayers treated with zileuton. 10 -6 M zileuton inhibited LTB4 release by 91% but did not significantly affect TXB2 release in IFN-y-treated monocyte-derived macrophages stimulated with the calcium ionophore A23187, confirming that zileuton is a selective 5-1ipoxygenase pathway inhibitor in these studies.
Discussion
We report here that T. gondii tachyzoites markedly alter eicosanoid metabolism in human mononuclear phagocytes. In particular, 5-1ipoxygenase arachidonic acid product release by these cells is suppressed by viable T. gondii. We found that LTB4 exerts cytotoxic activity against T. gondii tachyzoites promoting intraceUular killing of these organisms in monocyte-derived macrophages. Furthermore, the inhibition of IFN-'?-induced macrophage antitoxoplasma activity by selective inhibition of 5-1ipoxygenase suggests an important role for 5-1ipoxygenase products in the cytotoxic activity of these mononuclear phagocytes against T. gondii.
Our data indicate that, in metabolism of arachidonic acid by human monocytes, the profile of products released is dependent on the nature of the specific stimulus. Both cyclooxygenase (i.e., TXB/, PGEz) and 5-1ipoxygenase (i.e., LTB4, LTC4) products of arachidonic acid metabolism are released by normal human monocytes when stimulated by either particulate (i.e., opsonized zymosan particles, heat-killed T. gondii) or soluble (i.e., calcium ionophore A23187) stimuli. However, the monocytes (in comparison to nonstimulated control cells) fail to release significant amounts of 5-1ipoxygenase products after ingestion of viable T gondii. Possible explanations for this finding include the following: (a) LTs formed by T. gondii-stimulated normal human monocytes are degraded by MPO-H2Oz-halide system oxidants or hydroxyl radicals (OH.) released by the phagocytes (25) ; and (b) T. gondii do not activate the 5-1ipoxygenase pathway of arachidonic acid metabolism. Our findings suggest the second mechanism. CGD monocytes, which are unable to respond to stimulation with a respiratory burst and thus cannot oxidatively degrade LTs, also failed to release 5-1ipoxygenase products after incubation with T. gondii. As in normal monocytes, only cyclooxygenase pathway activation occurs in T. gondii-stimulated CGD monocytes.
Cyclooxygenase arachidonate products were the predominant eicosanoids released by monocytes ingesting viable T.
gondii or opsonized zymosan (88.7 and 68.0% of total eicosanoids, respectively). TXB2 was the predominant eicosanoid released by zymosan-stimulated human monocytes, in agreement with previous studies (35) . Similarly, we found that the monocytes after interaction with T. gondii primarily release TXB2. We recently reported that human platelets are cytotoxic to T. gondii tachyzoites, and TX release is important in this platelet-mediated toxoplasmacidal activity (21) . Surface membrane vesiculation and cytoplasmic lysis in the T. gondii are prominent ultrastructural features of TXA2-induced injury (21) . It is possible that TX generation by freshly isolated monocytes may contribute to the previously demonstrated (2) cytotoxic effect of these cells against T. gondii.
In monocytes, the soluble stimulus calcium ionophore A23187 primarily induced the release of 5-1ipoxygenase arachidonate products (89.5% of total eicosanoids assayed), in agreement with previous studies (35) (36) (37) (38) . LTB4 was the major product of calcium ionophore A23187-stimulated monocytes, with a ratio of TXBjPGE2/LTB4/LTC4 of 6:1:54:7 observed. The calcium ionophore A23187 also markedly increased (i.e., up to 30.4-fold) the total amount of eicosanoids released by the monocytes compared with that induced by the particulate stimuli. Prior incubation of the cells with viable T gondii did not significantly alter this pattern, with a ratio of TXB2/PGEjLTB4/LTC4 of 7:1:43:6 observed. These data indicate that T. gondii do not inhibit activation of the 5-1ipoxygenase pathway by a second stimulus in fleshly isolated monocytes.
Trippet al. (39) have reported that when murine peritoneal macrophages are maintained in tissue culture, there is a progressive decrease in the capacity of these cells to metabolize arachidonic acid. By 4 d in culture, they noted a minimum release of both cyclooxygenase (i.e., 6-keto-PGEl~, PGE2, TXB2) and 5-1ipoxygenase (i.e., LTC4) products by these macrophages. Similarly, we observed that as human monocytes differentiate in culture to monocyte-derived macrophages, there is a marked reduction in the ability of these cells to release eicosanoids after incubation with either soluble or particulate stimuli. In general, 5-1ipoxygenase product release was inhibited to a greater extent than cyclooxygenase product Figure 6 . Effect of LTB4 on intracellular killing of T gondii by human monocyte-derived macrophages. Non-IFN-y-treated day-5 monocyte-derived macrophages were incubated with T. gondii (1:5 ratio, monocyte-derived macrophage/organism) for 30 min at 37~ washed to remove noningested organisms, and then incubated in the absence (A) or presence (B) of 10 -6 M LTB4 and 10% autologous serum that was negative for Toxoplasma-specific release in the monocyte-derived macrophages. Monolayers maintained in culture for 5 d produced 12.7-fold less total eicosanoids after calcium ionophore A23187 stimulation than comparably activated freshly isolated monocytes. LTB4 and LTC4 release was decreased 16.3-and 44.4-fold, respectively (17.6-fold decrease in 5-1ipoxygenase products), whereas TXB2 and PGE2 release were decreased 4.1-and 2.8-fold, respectively (3.8-fold decrease in cyclooxygenase products) in the calcium ionophore A23187-stimulated day 5 monolayers. Release of LTB4 and TXB2 by calcium ionophore A23187-stimulated day 5 monolayer cells was still significantly greater than that of unstimulated controls, however. In zymosanstimulated monocyte-derived macrophages, a 2.7-fold decrease in total eicosanoids (4.4-fold decrease in 5-1ipoxygenase products and 2.3-fold decrease in cyclooxygenase products) released compared with zymosan-activated monocytes was observed.
In day 5 monolayers incubated with T. gondii, eicosanoid release was decreased to a greater extent than in cells incubated with zymosan particles. Although freshly isolated monocytes release both TXB2 and PGE2 after ingestion of T. gondii, monocytes maintained in culture for 5 d are not stimulated by T. gondii to release these cyclooxygenase products. Compared with freshly isolated monocytes, total eicosanoid release fell ninefold in monocyte-derived macrophages incubated with T. gondii, with a 15.5-and 9.5-fold reduction in release of TXB2 and PGE2, respectively. Furthermore, infection of the day-5 monocyte-derived macrophages by T.gondii prevented 5-1ipoxygenase pathway activation by a second stimulus, the calcium ionophore A23187. Failure of T. gondii-infected monocyte-derived macrophages to release eicosanoids (e.g., TXB2 and LTB4) that exert toxoplasmacidal activity may be important in the inability of human monocyte-derived macrophages to kill these parasites.
We have previously demonstrated that T. gondii cell membranes are disrupted by the cyclooxygenase product TXA2 (generated by platelet microsomal fractions) (21) and by the linoleic acid metabolite 13-hydroxyoctadecadienoic acid (31) but not by the 12-1ipoxygenase product 12-HETE released by T. gondii-stimulated human platelets (26) . As shown in this report, the 5-1ipoxygenase arachidonate product LTB4 also exerts potent cytotoxic activity against T. gondii tachyzoites. LTB4 induced surface membrane vesiculation, leakage of cytoplasmic contents into the space between the inner and outer surface membrane units, and intracytoplasmic vacuolation in T. gondii. Comparable cytotoxic changes occur in T. gondii after incubation with 10 -6 M LTC4 for 30 rain at 37~ (Chi, E. Y., and Henderson, W. R., Jr., unpublished observations). We have also found that incubation of T.
gondii-infected non-IFN-3,-treated monocyte-derived macrophages with LTB4 (10 -6 M) for 30 rain results in intracellular killing of the pathogens in contrast to intracellular replication of the T. gondii and disruption of the infected macrophages incubated in the absence of LTB4. LTB4 is a potent chemoattractant for human neutrophils and monocytes in vitro and in vivo (40, 41) . T. gondii-induced inhibition of mononuclear phagocyte LTB4 release could be an important antiinflammatory mechanism used by the parasites to diminish the influx of leukocytes into the tissue sites of T, gondii infection.
We also examined the effect of IFN-3, activation of the human mononuclear phagocytes on the metabolism of arachidonic acid by these cells. Prior studies have shown that activation of murine peritoneal macrophages results in an alteration in both the release of arachidonic acid and profile of generated eicosanoids that is dependent on whether the cells are activated in vivo or in vitro and the specific stimulus triggering eicosanoid release.
In C. parvum (44) or Listeria monocytogenes (45) . For example, TXA2 synthesis in L. monocytogenes-activated macrophages after zymosan stimulation is not significantly different from resident peritoneal macrophages, whereas total release of eicosanoids by the elicited cells is decreased by 94% compared with resident macrophages after incubation with zymosan (45) . In contrast, in vitro activation of murine peritoneal macrophages by IFN-3/results in diminished release of thromboxane (46) as well as PGI2 (46) The nature of the stimulus triggering eicosanoid synthesis also affects the profile of cyclooxygenase and 5-1ipoxygenase products released by activated macrophages in comparison to resident cells. As described above, IFN-y treatment of mufine peritoneal macrophages inhibits zymosan-induced release of both arachidonic acid (46) and all cyclooxygenase (i.e., PGE2, TXB2, PGI2) and 5-lipoxygenase (i.e., LTB4, LTC4) arachidonate products. However, while arachidonic acid and LTC4 release is decreased in calcium ionophore A23187-stimulated IFN-y-activated murine peritoneal macrophages, TXA2 release is unaffected, and PGE2 and PGI2 release is augmented compared with resident cells (46) . Furthermore, total arachidonic acid release is increased in these IFN-3~-treated cells after PMA stimulation, which also increases the release of PGE2 and PGI2 (46) .
Conflicting reports on the effects of IFN-3/ on human monocyte eicosanoid release have been published. In one study (48) , IFN-3 ~ (500 U/ml)-treatment of monocytes produced decreased release of PGE2, TXB2, PGF2~, and LTC4 after concanavalin A stimulation. However, in monocytes treated with IFN-y at a concentration of 10 U/ml and then stimulated with LPS, different effects on eicosanoid release have been observed. Nichols and Garrison (49) reported that such treatment increases PGE2 release without affecting TXB2 release by these cells. In contrast, Browning and Kibolini (50) found that PGE2 release was decreased and TXB2 release was increased in monocytes pretreated with IFN-'y before LPS stimulation.
We found that incubation of human monocytes with IFN-3' (100 U/ml) for 5 d in culture did not significantly affect the release of either cyclooxygenase or 5-1ipoxygenase products by the monocyte-derived macrophages after incubation with one of the following stimuli: zymosan, the calcium ionophore A23187, or heat-killed T. gondii. However, IFN-3' restored the ability of T. gondii-infected monocyte-derived macrophages to release LTB4 after calcium ionophore A23187 stimulation. The inhibition of IFN-'y-mediated toxoplasmacidal activity by the selective 5-1ipoxygenase inhibitor zileuton suggests that 5-1ipoxygenase arachidonic acid metabolites play an important role in the mediation of this cytotoxic activity.
In summary, these data indicate that T. gondii tachyzoites fail to activate the 5-1ipoxygenase pathway in human monocytes and suppress activation of this pathway in monocytederived macrophages. This inhibition of mononuclear phagocyte 5-1ipoxygenase product release may be important for the survival of these pathogens in vivo.
